We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
-28.56%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$185M
AUM Growth
-$98.2M
Cap. Flow
-$1.98M
Cap. Flow %
-1.07%
Top 10 Hldgs %
89.7%
Holding
21
New
–
Increased
–
Reduced
2
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
OBSV
ObsEva SA Ordinary Shares
OBSV
+$1.46M
2
HRMY icon
Harmony Biosciences
HRMY
+$514K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$61.6M 33.24%
6,068,125
– –
GLUE icon
2
Monte Rosa Therapeutics
GLUE
$1.4B
$20.6M 11.14%
1,472,331
– –
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.69B
$17.8M 9.61%
1,025,000
– –
HRMY icon
4
Harmony Biosciences
HRMY
$2.04B
$16.7M 9%
342,815
-12,600
-4% -$514K
NUVB icon
5
Nuvation Bio
NUVB
$2.2B
$13.4M 7.21%
2,541,009
– –
ACRS icon
6
Aclaris Therapeutics
ACRS
$726M
$10.9M 5.9%
634,455
– –
ELEV
7
DELISTED
Elevation Oncology
ELEV
$7.14M 3.86%
2,834,910
– –
TRML
8
DELISTED
Tourmaline Bio
TRML
$6.72M 3.63%
68,292
– –
VRNA
9
DELISTED
Verona Pharma
VRNA
$6.65M 3.59%
1,332,485
– –
PSTX
10
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$4.67M 2.52%
1,043,267
– –
SYRE icon
11
Spyre Therapeutics
SYRE
$8.54B
$3.89M 2.1%
67,646
– –
BMEA icon
12
Biomea Fusion
BMEA
$84.6M
$3.56M 1.92%
798,757
– –
OKUR
13
OnKure Therapeutics
OKUR
$154M
$2.6M 1.41%
88,608
– –
SPRB
14
Spruce Biosciences
SPRB
$118M
$2.42M 1.31%
16,073
– –
MRKR icon
15
Marker Therapeutics
MRKR
$18.8M
$1.38M 0.75%
314,286
– –
VIRX
16
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.37M 0.74%
288,571
– –
TECX
17
Tectonic Therapeutic
TECX
$529M
$1.33M 0.72%
84,148
– –
BCEL
18
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$1.23M 0.66%
387,653
– –
ZSAN
19
DELISTED
Zosano Pharma Corporation
ZSAN
$612K 0.33%
77,664
– –
OBSV
20
DELISTED
ObsEva SA Ordinary Shares
OBSV
$596K 0.32%
394,838
-991,500
-72% -$1.46M
NBRV
21
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$80K 0.04%
7,641
– –

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Aisling Capital Management held 21 positions worth $185M, down 35% from $283M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Trading was light in Q1 2022: portfolio turnover was 0%. Aisling Capital Management opened no new positions and made no exits, leaving the 21-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management's biggest Q1 2022 reduction was ObsEva SA Ordinary Shares, cutting an estimated $1.46M.
  • Aisling Capital Management's ten largest holdings make up 90% of its $185M portfolio in Q1 2022.
  • Aisling Capital Management opened 0 new positions and closed 0 in Q1 2022.
  • Aisling Capital Management's portfolio value fell 35% quarter-over-quarter to $185M.

Based on Aisling Capital Management's 13F filing for Q1 2022, filed 10 May 2022.